VivoSeq
Other

Inflammatory Disease

0

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Inflammatory Disease is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, Merck & Co., UCB.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

69/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalUCB logo

UCB

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed9 · 47%
Recruiting4 · 21%
Terminated3 · 16%
Unknown status1 · 5%
Active, not recruiting1 · 5%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

19 trials

China National Registry of Neuro-Inflammatory Diseases
Recruiting·—·N/A·NCT05154370·10,000 enrolled
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Recruiting·UUMC Utrecht·Phase 2·NCT06285539·60 enrolled
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Recruiting·TTongji Hospital·Phase 1·NCT04561557·36 enrolled
Safety and Efficacy of Capsule FMT in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases
Recruiting·OOdense University Hospital·Phase 2·NCT04924270·200 enrolled
Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations
Active, not recruiting·Novartis logoNovartis·Phase 2·NCT04641442·17 enrolled
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
Completed·Merck & Co. logoMerck & Co.·N/A·NCT00727298·4,485 enrolled
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT01988506·81 enrolled
Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat
Completed·Novartis logoNovartis·Phase 3·NCT03095508·229 enrolled
Interleukin-1 Trap to Treat Autoinflammatory Diseases
Completed·National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 2·NCT00094900·11 enrolled
A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases
Completed·GGalapagos NV·Phase 1·NCT03800472·95 enrolled
Safety, Tolerability and Efficacy of GcMAF in Patients With Chronic Inflammatory Diseases
Completed·SS.LAB (SOLOWAYS)·Phase 1/2·NCT06877364·120 enrolled
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
Completed·UCB logoUCB·Phase 1·NCT04163016·22 enrolled
Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases
Completed·—·N/A·NCT02839278·150 enrolled
Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases
Completed·UUniversity Hospital, Bordeaux·N/A·NCT02280902·72 enrolled
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases
Terminated·UUniversity Hospital, Lille·N/A·NCT03370601·9 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)